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httpcense.Abstract Background: Regulatory T-cells are CD4+ cells involved in the regulation of suppres-
sion of immune response during infection. Many studies revealed that the number of these cells,
increase in patients with active pulmonary TB (PTB. Few studies addressed this problem in
MDR-PTB.
Objective: This work aimed at studying some T reg – cell subsets in patients with MDR-PTB,
compared to those with active pulmonary TB who responded to treatment as well as to healthy con-
trol subjects.
Methods: Three groups were included in the study (20, in each group), group of healthy control
and 2 groups as patients’ groups (patients with MDR-PTB and patients’ with PTB responding to
treatment). Routine blood work and CXR were done for all subjects in addition to microbiological
evaluation of sputum in patients’ groups. T reg – cell subsets in peripheral blood were studied by
ﬂow cytometry, using monoclonal antibodies against the following markers, CD4, CD25 and
FoxP3 for identiﬁcation.
Results: Patients’ groups, had higher frequency of T reg cell subsets, CD4+ CD25+ FoxP3+
than the group of healthy subject, (P< 0.01) and treatment responders’ group had non-signiﬁ-
cantly higher percentage of these cells than in patients with MDR-PTB (P> 0.05), but highly01003209654.
(S. Labib).
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622 S. Labib et al.signiﬁcant statistical difference for the percentage of total CD4+ (P< 0.01). Patients’ with more
radiologically extensive disease, had higher level of these cells than, in other patients (P< 0.05),
with signiﬁcant positive correlation.
Conclusion: Although immune suppression characteristic of T reg – cells seems important in the
pathogenesis of MDR-PTB, other mechanisms, immunologic, on non-immunologic are important
as well.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. Open access under CC BY-NC-ND license.75.0
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In 2010, there were 8.8 million (range, 8.5–9.2 million) new
cases of TB, 1.1 million (range, 0.9–1.2 million) deaths from
TB among HIV – negative people and an additional 0.35 mil-
lion (range, 0.32–0.39 million) deaths from HIV-associated
TB. According to the WHO report about global tuberculosis,
ﬁve of six WHO regions (the exception being the African Re-
gion) are on track to achieve the stop TB partnership target of
halving 1990 mortality rates by 2015. Yet, alongside this
achievement, diagnosis and appropriate treatment of multi-
drug-resistant TB (MDR-TB) remain major challenges. In
2010, there were an estimated 650,000 cases of MDR-TB
among the world’s 12.0 million prevalent cases of TB [1].
T-cells, termed T regulatory (T reg) cells, which have immu-
nosuppressive functions and cytokine proﬁles distinct from
that of either Th1 or Th2 cells, have been intensely investigated
during recent years [2]. TB induces a state of immune activa-
tion in the infected host, and an increased expression of activa-
tion markers on T cells in blood from patients with active TB
has been described [2,3]. T regulatory cells (T reg) are CD4+ T
cells involved in the regulation of self-tolerance, autoimmunity
and suppression of immune responses during infections [4,5]. T
reg – cells were ﬁrst recognized as FoxP3+ CD4 + CD25+ T
cells, but expression of the intracellular marker forkhead box
p3 (FoxP3) and low cell-surface expression of the IL-7 receptor
a-chain (CD127) have been suggested as more accurate mark-
ers. Many studies suggested a role of T reg in immune response
to mycobacteal infection as it seems to be an increased level of
immune activation and T reg in both latent and active TB
infection that is only modestly inﬂuenced by preventive ther-
apy. In Germany, latent infection with Mycobacterium tuber-
culosis is characterized by an increased frequency of T reg –
cells in the bronchoalveolar lavage (BAL) [5]. Compared with
controls, tuberculosis had the highest T reg cell frequency, but
also the highest levels of CD4+ T lymphocyte activation [3].
Heet et al. (2010) hypothesized that this susceptibility toM.
Tuberculosis infection is linked to increased T regulatory (T
reg) cells and Th2 cytokines in tuberculosis patients. CD4+
FoxP3+ regulatory. T-cell expansion in the lung suggests that
T reg – cells may be related to the progression of M. tubercu-
losis infection and that the balance [6] between effector im-
mune responses and suppression of immune responses is
essential to control M. tuberculosis infection.
Many studies revealed that the number of T reg – cells in-
creases in the blood and at the infection site in active TB patients
[7–9] and in latent M. tuberculosis infection [5]. However, few
studies had addressed this problem inMDRTB patients [10,11].
The aim of this study was to assess some regulatory T-cell
subsets in patients with MDR-TB in comparison to patientswith active pulmonary TB who responded to anti-TB drugs
as well as to healthy control subjects.
Patients and methods
This case control, cross-sectional study was conducted in chest
unit, n medicine department, clinical pathology and microbiol-
ogy departments, Suez Canal University in collaboration with
Abbassia Chest and Ismailia Chest Hospitals.
The study included 3 groups of patients with pulmonary
tuberculosis (P-TB), 20 patients in each group and a 3rd group
of 20 healthy volunteers.
Group I: comprised re-treatment cases of P-TB (relapse,
treatment failure and defaulters) whose sputa were positive
for AFB with multidrug – resistance (MDR-TB). All patients
in this group were negative for HIV.
Group II: comprised patients with newly-diagnosed smear
positive active PTB who had received anti-TB drugs for at least
2 months and responded well, clinically, radiologically, and
bacteriologically (i.e. sputum was negative for AFB at the
end of the initiation period).
Group III: included 20 healthy volunteers with matched
age, sex and all subjects had negative tuberculin skin testing.
All patients were subjected to the following
– Complete medical history and careful clinical examination.
– Chest X-ray, postero-anterior and lateral views (all subject)
as a diagnostic tool and to assess the radiological extent as
mild, moderate and far-advanced (or extensive). (National
tuberculosis Association of USA, 1961) [12].
– Sputum examination for AFB by Zeihl – Neelsen stain.Fig. 1 Comparison between three groups as regards sex.
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Fig. 2 Comparison between three groups as regards age,
smoking index and weight (kg).
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Fig. 3 Comparison between three groups as regards associated
disease (DM).
Study of some T regulatory cell subsets in patients with multi-drug resistant pulmonary tuberculosis 623– Routine blood work (all study subjects), including CBC,
ESR, LFTs, S-creatinine, fasting and 2-h post prandial
sugar and HIV screening (in group I only).
– Patients in group I were also subjected to sputum culture on
Lowenstein- ensen medium and drug – susceptibility testing
for ﬁrst line anti-TB drugs.
– Flow cytometric study of monocyte – depleted peripheral
blood mono-nuclear cells (PBMC) and dis included (DH)
CD25 and Fox P3 +ve regulatory T-cells (T regs).
T reg subset study by ﬂowcytometer
Anticoagulated blood was collected in EDTA vacutainer
tubes. T reg subsets regarding their CD25 and foxp3 were iden-
tiﬁed using monoclonal antibodies for the following markers,
CD4 antibodies labeled by FITC ﬂuorochrome, anti FOXP3
labeled by PE ﬂuorochrome and, anti CD25 labeled by APC
ﬂuorochrome. Surface staining was done ﬁrst for both CD4
and CD25 according to the regular procedures, then it was fol-
lowed by cellular permeabilization and intracellular staining
for FOXP3. After staining, data acquisition by FACS calibur
using cell quest software and paint gate software for data anal-
ysis was done. (BD Bio-sciences, San Jose´, CD, USA).
Statistical analysis
Data were analyzed using Statistical Program for Social Sci-
ence (SPSS) version 18.0. Quantitative data were expressed
as mean ± standard deviation (SD). Qualitative data were ex-
pressed as frequency and percentage.
The following tests were done
 Independent-sample t-test of signiﬁcance was used when
comparing between two means.CD4+CD25- FoxP3+
25+ FoxP3-
2 TR G3 HC
ups as regards T reg – cell subsets.
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Fig. 5 signiﬁcantly positive Correlation between radiological extent and T reg – cell subsets.
Table 1 Comparison between three groups as regards sex.
Sex Groups Total
G1 MDR G2 TR G3 HC
No. % No. % No. % No. %
Male 15 75.00 14 70.00 14 70.00 27 45.00
Female 5 25.00 6 30.00 6 30.00 33 55.00
Total 20 100.00 20 100.00 20 100.00 60 100.00
X2 10.909
P-value 0.052
MDR: multidrug resistance; TR: treatment responders; HC: healthy control; X2: chi-square test.
There is no signiﬁcant difference among the study groups regarding sex, P-value >0.05.
624 S. Labib et al. A one-way analysis of variance (ANOVA) when comparing
between more than two means. Chi-square (X2) test of signiﬁcance was used in order to
compare proportions between two qualitative parameters.
Table 2 Comparison between three groups as regards age, smoking index and weight (kg).
Parameters G1 MDR G2 TR G3 HC ANOVA LSD
Mean ±SD Mean ±SD Mean ±SD F P-Value I & II I & III II & III
Age 41.60 14.28 43.30 15.26 40.75 15.61 33.71 0.862 0.722 0.859 0.594
Smoking index 528.44 253.93 578.24 321.25 142.00 27.75 3754.13 0.016* 0.668 0.019* 0.005**
Weight (kg) 51.68 9.91 59.40 9.59 72.80 13.68 2285.01 <0.001 0.034* <0.001** <0.001**
MDR: multidrug resistance; TR: treatment responders; HC: healthy control. F: ANOVA test; LSD: least signiﬁcant difference.
* P-value <0.05 S.
** P-value <0.01 HS. There is a highly statistically signiﬁcant difference between patients’ groups and healthy control group regarding weight,
P-value <0.001 and signiﬁcant statistical difference regarding smoking index, P-value <0.05.
Table 3 Comparison between three groups as regards associated disease (DM).
Associated disease (DM) Groups x2/t* P-Value
G1 MDR G2 TR
No. % No. %
No 16 80.00 12 60.00 1.905 0.168
Yes 4 20.00 8 40.00
Total 20 100.00 20 100.00
Duration in year (DM)
Mean ± SD 23.0 ± 10.37 20.0 ± 7.07 0.491* 0.638
MDR: multidrug resistance; TR: TREATMENT responders; HC: Healthy control; X2: Chi-square test; t: Independent sample t-test.
There is no statistically signiﬁcant difference among the patients’ groups regarding the incidence and duration of diabetes mellitus (DM), P-
value >0.05.
Table 4 Comparison between three groups as regards T reg – cell subsets.
Parameters G1 MDR G2 TR G3 HC ANOVA LSD
Mean ±SD Mean ±SD Mean ±SD F P-Value I & II I & III II & III
Lymphocytes% 25.95 8.43 24.10 6.32 32.78 4.41 4154.046 <0.001** 0.437 0.002** <0.001**
CD4+ 32.30 9.97 21.75 8.28 32.10 5.30 728.217 <0.001** <0.001** 0.938 <0.001**
CD4+CD25FoxP3+ 27.35 12.81 32.70 9.39 16.55 3.55 1353.617 <0.001** 0.077 <0.001** <0.001**
CD4+CD25+ FoxP3+ 13.90 6.57 18.30 9.72 6.04 1.22 771.491 <0.001** 0.056 0.003** <0.001**
CD4+CD2+ FoxP3 15.80 5.81 13.60 4.24 20.35 3.82 237.017 <0.001** 0.144 0.003** <0.001**
MDR: multidrug resistance; TR: treatment responders; HC: healthy control; F: ANOVA test; LSD: Least signiﬁcant difference.
** P-value <0.01 HS. There are highly statistically signiﬁcant differences between patients’ groups and healthy control group regarding T reg –
cell subsets. There is highly signiﬁcant statistical difference between both patients’ groups regarding CD4+ cells.
Table 5 Correlation between age, smoking, weight, radiological extent, duration of DM and T reg – cell subsets.
Parameters CD4+ CD4+ 25-FOX+ CD4+ 25 + F0X+ CD4+25+FOX-
r P-Value r P-Value r P-Value r P-Value
Age 0.278 0.082 0.046 0.778 0.015 0.925 0.248 0.122
Smoking index 0.137 0.503 0.040 0.846 0.027 0.897 0.121 0.557
Weight (kg) 0.270 0.092 0.042 0.798 0.124 0.447 0.028 0.863
Radiological extent 0.531 0.037* 0.871 0.045* 0.633 0.037* 0.793 0.032*
Duration in years (DM) 0.080 0.838 0.098 0.802 0.295 0.440 0.189 0.626
r: pearson correlation co-efﬁcient test.
* P-Value <0.05. There is signiﬁcant positive correlation between the radiological extent and studied T reg – cell subsets; other parameters show
non-signiﬁcant correlation.
Study of some T regulatory cell subsets in patients with multi-drug resistant pulmonary tuberculosis 625 Pearson’s correlation coefﬁcient (r) test was used for corre-
lating data. Probability (P-value)
– P-value < 0.05 was considered signiﬁcant.
626 S. Labib et al.– P-value 0.01 was considered as highly signiﬁcant.
– P-value > 0.05 was considered non-signiﬁcant.
Results
Figs. 1–5 and Tables 1–5.
Discussion
Multidrug – resistant TB (MDR-TB) and the recently de-
ﬁned cases of extensively drug-resistant (XDR-TB) and even
totally drug resistant TB constitute major health problems
[13,14].
In patients with drug – resistance, an impaired Th1 immune
response was described [15,16]. However, the mechanisms of
this deﬁciency remain elusive.
In our study, the frequency of T reg-Cells was increased in
the blood of patients with multidrug – resistant pulmonary
tuberculosis (MDR-PTB) as well as in patients who responded
well to anti-tuberculosis treatment when compared to healthy
control, tuberculin skin test-negative subjects with signiﬁcant
statistical difference (P< 0.05). These results are consistent
with previous studies by He et al. [3] Chen et al. [17] and Sem-
ple et al. [18] who found that the levels of these cells were high-
er in patients with active pulmonary tuberculosis than in
healthy control subjects. Pinheiro et al. [11] showed that the
PBMC from patients with MDR-PTB had signiﬁcantly higher
percentage of CD4+ CD25+ FoxP3+ and CD4+ CD25+
CD127 cells than in healthy control subjects. In the present
study, we found that the level of CD4+ CD25+ Fox P3+
was higher in responders to treatment than in patients with
MDR-PTB with non-signiﬁcant statistical difference
(P< 0.05). These results are not in agreement with the study
done by Pinheiro et al. [8], who found that the level of these
cells was higher in patients MDR-TB. Our results could be a
explained by the T reg – cell dynamics (or re-distribution)
between the blood and the sites of infection/inﬂammation as
suggested by Semple et al. [18], which is augmented overtime
with persistence of the drug-resistant TB bacilli. These cells
modulate the immune response to decrease tissue damage in
cases of chronic infection like MDR-PTB.
Another explanation is the fact that we did not study other
T reg-cell subsets like, CD4+, CD25+, CD39+ [19], CD4+
CD25+ CD127- [11,20] and CD8+CD45 RA+ CCR7+
FoxP3+[21] which could have increased levels in the blood
of patients with MDR-PTB. Our results are in agreement with
the studies of Ribeiro et al. [22] and Semple et al. [18], which
showed an increase in T reg – cell frequency in the disease-in-
volved lung, compared to PBMCs of PTB patients.
Herzmunn et al. [5] found an increase in the level of T reg –
cells in subjects with latent TB infection when compared to
those with negative tuberculin skin testing. In our study all
the healthy control subjects had negative testing.
The radiological extent of lesions with more extensive ones
in the present study in either group of patients (groups I and
II) showing signiﬁcant positive correlation with the number
of T reg – cells and this result is consistent with those of
Pinheiro et al. [11] and Dheda et al. [23] On the other hand,
the age, smoking index, the duration of associated DM showed
non-signiﬁcant correlation with the number of T reg – cells.In summary, the study disclosed that the frequency of
CD4+, CD25+, FoxP3+, cells was higher in the blood of
both patients with MDR-PTB and responders to treatment,
compared to healthy subjects and there was non-signiﬁcant
statistical difference between both patients’ groups regarding
the level of these cells. It is concluded that, although immune
suppression characteristic of T reg – cells seems important in
the pathogenesis of MDR-PTB, other mechanisms, immuno-
logic or non-immunologic are important, as well. More stud-
ies with larger number of patients are needed to study
different T reg. cell subsets in both the blood and the lungs
of patients with MDR-PTB.Conﬂict of interest
None.
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